melbarowlandso

Mannetje
Sociale links
Bio
Most evidence shows that testosterone therapy can cause a small, temporary rise in PSA, especially in the first few months of treatment. That’s why doctors use the PSA test as an early signal of possible prostate disease, including prostate cancer. The connection between PSA and testosterone remains an area of medical scrutiny, with evidence suggesting that while TRT may cause mild PSA increases, it does not inherently lead to prostate cancer. If your PSA levels increase while on testosterone therapy, the first step is to assess whether the change is significant or within an expected range.
It is often used as a marker to help detect prostate problems, including cancer. Testosterone affects the prostate by increasing cell activity and PSA production, but this does not automatically mean cancer is developing. Once the androgen receptors in the prostate are "saturated," adding more testosterone does not make the cells grow or produce PSA faster. This is known as the "saturation model." According to this theory, prostate cells need only a certain amount of testosterone to function at their maximum rate.
If you are considering or already on TRT, it is essential to talk to your doctor about how to monitor your PSA levels. However, it is important to understand that TRT can also affect the prostate, a small gland in men that plays a key role in reproductive health. By making simple lifestyle changes, paying attention to your diet, staying active, and considering complementary therapies, you can help keep your PSA levels in a healthy range. Some studies suggest that acupuncture may help reduce PSA levels, though more research is needed. Good circulation helps your prostate function better and can help lower PSA levels. Losing weight and maintaining a healthy weight can help reduce your PSA levels and improve your overall health.
Keeping your medical care coordinated helps ensure that all aspects of your health—hormonal, prostate, and general—are managed safely. You should make sure both specialists communicate with each other, especially if your PSA levels rise or if you develop urinary symptoms. The doctor will usually check your PSA before you start treatment, then again a few months after beginning TRT, and regularly after that—often every 6 to 12 months. Talking openly with your doctor before and during therapy is one of the best ways to stay safe and get the most benefit.
In some cases, PSA levels may decline after discontinuing testosterone therapy, but this depends on several factors, including baseline PSA, prostate health, and duration of TRT use. One of the most debated topics regarding testosterone therapy is whether it contributes to prostate cancer risk. By tracking PSA trends over time, your doctor can assess whether testosterone therapy is affecting your prostate health.
Testosterone helps regulate how prostate cells grow and function. This means that the body adjusts, and PSA stops rising once testosterone reaches a steady level in the blood. However, not all PSA increases mean there is something dangerous happening. For most men with low testosterone, these findings are reassuring and support that TRT, when prescribed appropriately, can be both effective and safe. If PSA rises sharply—typically more than 1.0 ng/mL within a year—further evaluation is needed.
This explains why men starting testosterone therapy sometimes see their PSA go up a little. Testosterone became seen as "fuel for the fire" when it came to prostate cancer. To understand this concern, it is important to look at where the idea came from, how testosterone affects the prostate, and what we now know from scientific studies. Men in these groups should discuss other options or be treated for underlying problems before considering testosterone therapy. If PSA levels rise more than expected, or if other concerning symptoms appear, therapy may be paused or adjusted until the cause is understood.
These include androgen deprivation therapy (ADT), which intentionally lowers testosterone levels to slow cancer progression. However, in general, anything over 10 ng/mL is linked to a 50% chance of prostate cancer, and the doctors will order more tests. Current research suggests that TRT does not significantly increase the risk of developing prostate cancer.
At least separate two measurements of serum testosterone should be taken to confirm any biochemical diagnosis of hypogonadism. Compared to matched controls, there was no difference between the two groups in terms of IPSS, Qmax, PVR or prostate size. The concept, therefore, that treatment with TRT of hypogonadal males with metabolic syndrome might lead to improvement/stabilization of their LUTS, appears to be confirmed in recent work by Francomano et al.44 They published data in which 20 obese, hypogonadal men with metabolic syndrome were treated with TRT and followed for 5 years. When compared with those without metabolic syndrome (and corrected for age and serum testosterone), they had a worse IPSS, larger TPV, and larger PVR volume. Park et al.38 investigated a group of 1224 otherwise healthy police officers, 29% of whom were diagnosed with metabolic syndrome.
https://nauticauruguay.com/stanw948045136/2993949/wiki/Well-The-New-York-Times

Muziek doorzoeken

Op te slaan

Jouw muziek

melbarowlandso

Kunstenaars om te volgen

Wekelijkse toptracks

Role Model 1.0

Wachtrij